{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:33:29Z","timestamp":1790696009736,"version":"4.1.0"},"reference-count":96,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":584,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008762","name":"Genome Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008762","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000233","name":"Genome British Columbia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000233","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004376","name":"Terry Fox Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004376","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009447","name":"Leukemia and Lymphoma Society of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009447","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.exphem.2020.09.196","type":"journal-article","created":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T08:58:47Z","timestamp":1602233927000},"page":"22-31","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"special_numbering":"C","title":["Mechanisms of lenalidomide sensitivity and resistance"],"prefix":"10.1016","volume":"91","author":[{"given":"Sergio","family":"Martinez-H\u00f8yer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aly","family":"Karsan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2020.09.196_bib0001","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1084\/jem.173.3.699","article-title":"Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes","volume":"173","author":"Sampaio","year":"1991","journal-title":"J Exp Med"},{"key":"10.1016\/j.exphem.2020.09.196_bib0002","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1073\/pnas.91.9.4082","article-title":"Thalidomide is an inhibitor of angiogenesis","volume":"91","author":"D'Amato","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.exphem.2020.09.196_bib0003","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1084\/jem.187.11.1885","article-title":"Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset","volume":"187","author":"Haslett","year":"1998","journal-title":"J Exp Med"},{"key":"10.1016\/j.exphem.2020.09.196_bib0004","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1182\/blood.V98.1.210","article-title":"Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma","volume":"98","author":"Davies","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2020.09.196_bib0005","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America","volume":"357","author":"Weber","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2020.09.196_bib0006","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2020.09.196_bib0007","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1182\/blood-2013-11-538835","article-title":"Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study","volume":"123","author":"Richardson","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2020.09.196_bib0008","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa041668","article-title":"Efficacy of lenalidomide in myelodysplastic syndromes","volume":"352","author":"List","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2020.09.196_bib0009","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1200\/JCO.2013.49.2835","article-title":"Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study","volume":"31","author":"Goy","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2020.09.196_bib0010","doi-asserted-by":"crossref","first-page":"5291","DOI":"10.1182\/blood-2007-12-130120","article-title":"Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia","volume":"111","author":"Ferrajoli","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2020.09.196_bib0011","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1182\/blood-2015-02-628669","article-title":"CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL","volume":"126","author":"Hagner","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2020.09.196_bib0012","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1021\/acs.jmedchem.6b01921","article-title":"A Cereblon modulator (CC-220) with improved degradation of Ikaros and Aiolos","volume":"61","author":"Matyskiela","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.exphem.2020.09.196_bib0013","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1126\/science.1177319","article-title":"Identification of a primary target of thalidomide teratogenicity","volume":"327","author":"Ito","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.exphem.2020.09.196_bib0014","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1182\/blood-2011-05-356063","article-title":"Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide","volume":"118","author":"Zhu","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2020.09.196_bib0015","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1038\/leu.2012.119","article-title":"Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide","volume":"26","author":"Lopez-Girona","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2020.09.196_bib0016","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kr\u00f6nke","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.exphem.2020.09.196_bib0017","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1126\/science.1244917","article-title":"The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins","volume":"343","author":"Lu","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.exphem.2020.09.196_bib0018","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nature14610","article-title":"Lenalidomide induces ubiquitination and degradation of CK1\u03b1 in del(5q) MDS","volume":"523","author":"Kr\u00f6nke","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2020.09.196_bib0019","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nature18611","article-title":"A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligase","volume":"535","author":"Matyskiela","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2020.09.196_bib0020","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/nm.4128","article-title":"Immunomodulatory drugs disrupt the cereblon\u2013CD147\u2013MCT1 axis to exert antitumor activity and teratogenicity","volume":"22","author":"Eichner","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.exphem.2020.09.196_bib0021","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1073\/pnas.1700949114","article-title":"p97\/VCP promotes degradation of CRBN substrate glutamine synthetase and neosubstrates","volume":"114","author":"Nguyen","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.exphem.2020.09.196_bib0022","doi-asserted-by":"crossref","first-page":"15398","DOI":"10.1038\/ncomms15398","article-title":"pSILAC mass spectrometry reveals ZFP91 as IMiD-dependent substrate of the CRL4CRBN ubiquitin ligase","volume":"8","author":"An","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.exphem.2020.09.196_bib0023","doi-asserted-by":"crossref","first-page":"eaat0572","DOI":"10.1126\/science.aat0572","article-title":"Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN","volume":"362","author":"Sievers","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.exphem.2020.09.196_bib0024","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1182\/blood.2019000789","article-title":"Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogs","volume":"134","author":"Sperling","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2020.09.196_bib0025","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1021\/acsmedchemlett.9b00597","article-title":"PROTAC technology: Opportunities and challenges","volume":"11","author":"Gao","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.exphem.2020.09.196_bib0026","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nature13527","article-title":"Structure of the DDB1\u2013CRBN E3 ubiquitin ligase in complex with thalidomide","volume":"512","author":"Fischer","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2020.09.196_bib0027","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nature16979","article-title":"Structural basis of lenalidomide-induced CK1\u03b1 degradation by the CRL4(CRBN) ubiquitin ligase","volume":"532","author":"Petzold","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2020.09.196_bib0028","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1182\/blood-2018-05-852798","article-title":"CrbnI391V is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice","volume":"132","author":"Fink","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2020.09.196_bib0029","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple myeloma","volume":"3","author":"Kumar","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.exphem.2020.09.196_bib0030","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1365-2141.2011.08689.x","article-title":"Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response","volume":"154","author":"Lopez-Girona","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2020.09.196_bib0031","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/bjh.12708","article-title":"Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.)","volume":"164","author":"Gandhi","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2020.09.196_bib0032","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.1158\/1078-0432.CCR-15-0200","article-title":"Lenalidomide enhances immune checkpoint blockade-induced immune response in multiple myeloma","volume":"21","author":"G\u00f6rg\u00fcn","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2020.09.196_bib0033","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1182\/blood-2015-01-625004","article-title":"Lenalidomide augments actin remodeling and lowers NK-cell activation thresholds","volume":"126","author":"Lagrue","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2020.09.196_bib0034","article-title":"Immunomodulatory drugs activate NK cells via both Zap-70 and cereblon-dependent pathways","author":"Hideshima","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2020.09.196_bib0035","first-page":"10155","article-title":"Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function","author":"Gandhi","year":"2010","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.exphem.2020.09.196_bib0036","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1182\/blood-2010-04-278432","article-title":"The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy","volume":"117","author":"Hsu","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2020.09.196_bib0037","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/sj.leu.2404067","article-title":"Bone marrow angiogenesis in multiple myeloma","volume":"20","author":"Vacca","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2020.09.196_bib0038","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1038\/sj.bjc.6600607","article-title":"Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects","volume":"87","author":"Dredge","year":"2002","journal-title":"Br J Cancer"},{"key":"10.1016\/j.exphem.2020.09.196_bib0039","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.mvr.2005.01.002","article-title":"Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro","volume":"69","author":"Dredge","year":"2005","journal-title":"Microvasc Res"},{"key":"10.1016\/j.exphem.2020.09.196_bib0040","doi-asserted-by":"crossref","first-page":"14604","DOI":"10.18632\/oncotarget.14654","article-title":"Inactivation of CK1\u03b1 in multiple myeloma empowers drug cytotoxicity by affecting AKT and \u03b2-catenin survival signaling pathways","volume":"8","author":"Manni","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.exphem.2020.09.196_bib0041","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41420-019-0179-1","article-title":"Prosurvival autophagy is regulated by protein kinase CK1 alpha in multiple myeloma","volume":"5","author":"Carrino","year":"2019","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.exphem.2020.09.196_bib0042","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/leu.2014.202","article-title":"CSNK1\u03b11 mediates malignant plasma cell survival","volume":"29","author":"Hu","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2020.09.196_bib0043","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-019-0173-0","article-title":"Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4","volume":"9","author":"Zhu","year":"2019","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.exphem.2020.09.196_bib0044","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/bjh.12172","article-title":"Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression","volume":"160","author":"Zhang","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2020.09.196_bib0045","doi-asserted-by":"crossref","first-page":"7254","DOI":"10.1158\/0008-5472.CAN-13-0750","article-title":"Lenalidomide inhibits lymphangiogenesis in preclinical models of mantle cell lymphoma","volume":"73","author":"Song","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2020.09.196_bib0046","first-page":"2427","article-title":"Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug","volume":"118","author":"Ramsay","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.exphem.2020.09.196_bib0047","doi-asserted-by":"crossref","first-page":"4713","DOI":"10.1182\/blood-2009-04-217687","article-title":"Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy","volume":"114","author":"Ramsay","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2020.09.196_bib0048","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ccr.2012.05.024","article-title":"Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma","volume":"21","author":"Yang","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.exphem.2020.09.196_bib0049","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1182\/blood-2014-03-559591","article-title":"Lenalidomide inhibits the proliferation of CLL cells via a cereblon\/p21(WAF1\/Cip1)-dependent mechanism independent of functional p53","volume":"124","author":"Fecteau","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2020.09.196_bib0050","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/nrc.2016.112","article-title":"The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia","volume":"17","author":"Sperling","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.exphem.2020.09.196_bib0051","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/ejh.13207","article-title":"Molecular pathogenesis of myelodysplastic syndromes with deletion 5q","volume":"102","author":"Lee","year":"2019","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.exphem.2020.09.196_bib0052","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nature06494","article-title":"Identification of RPS14 as a 5q\u2013 syndrome gene by RNA interference screen","volume":"451","author":"Ebert","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2020.09.196_bib0053","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/nm.4047","article-title":"Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9","volume":"22","author":"Schneider","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.exphem.2020.09.196_bib0054","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nm.2054","article-title":"Identification of miR-145 and miR-146a as mediators of the 5q\u2013 syndrome phenotype","volume":"16","author":"Starczynowski","year":"2010","journal-title":"Nat Med"},{"key":"10.1016\/j.exphem.2020.09.196_bib0055","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ccr.2014.08.001","article-title":"Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS","volume":"26","author":"Schneider","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.exphem.2020.09.196_bib0056","doi-asserted-by":"crossref","first-page":"264","DOI":"10.3389\/fonc.2014.00264","article-title":"PP2A: the Achilles heal in MDS with 5q deletion","volume":"4","author":"Sallman","year":"2014","journal-title":"Front Oncol"},{"key":"10.1016\/j.exphem.2020.09.196_bib0057","doi-asserted-by":"crossref","first-page":"12974","DOI":"10.1073\/pnas.0811267106","article-title":"A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide","volume":"106","author":"Wei","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.exphem.2020.09.196_bib0058","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/nm.4127","article-title":"A calcium- and calpain-dependent pathway determines the response to lenalidomide in myelodysplastic syndromes","volume":"22","author":"Fang","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.exphem.2020.09.196_bib0059","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/s41556-020-0497-9","article-title":"Loss of lenalidomide-induced megakaryocytic differentiation leads to therapy resistance in del(5q) myelodysplastic syndrome","volume":"22","author":"Martinez-H\u00f8yer","year":"2020","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.exphem.2020.09.196_bib0060","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.3324\/haematol.2018.188227","article-title":"Immunomodulatory drugs downregulate IKZF1 leading to expansion of hematopoietic progenitors with concomitant block of megakaryocytic maturation","volume":"103","author":"Liu","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2020.09.196_bib0061","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1182\/blood.2019003749","article-title":"Aromatase is a novel neo-substrate of cereblon responsible for immunomodulatory drugs-induced thrombocytopenia","volume":"135","author":"Tochigi","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2020.09.196_bib0062","doi-asserted-by":"crossref","first-page":"5943","DOI":"10.1200\/JCO.2007.15.5770","article-title":"Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes","volume":"26","author":"Sekeres","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2020.09.196_bib0063","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/bjh.15094","article-title":"Megakaryocytes harbour the del(5q) abnormality despite complete clinical and cytogenetic remission induced by lenalidomide treatment","volume":"180","author":"Scharenberg","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2020.09.196_bib0064","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1182\/blood.V88.4.1284.bloodjournal8841284","article-title":"Characterization of a bipotent erythro-megakaryocytic progenitor in human bone marrow","volume":"88","author":"Debili","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2020.09.196_bib0065","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/nature12495","article-title":"Platelet-biased stem cells reside at the apex of the haematopoietic stem-cell hierarchy","volume":"502","author":"Sanjuan-Pla","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2020.09.196_bib0066","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.stem.2015.05.003","article-title":"Functionally distinct subsets of lineage-biased multipotent progenitors control blood production in normal and regenerative conditions","volume":"17","author":"Pietras","year":"2015","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.exphem.2020.09.196_bib0067","doi-asserted-by":"crossref","first-page":"aab2116","DOI":"10.1126\/science.aab2116","article-title":"Distinct routes of lineage development reshape the human blood hierarchy across ontogeny","volume":"351","author":"Notta","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.exphem.2020.09.196_bib0068","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nature25455","article-title":"Hierarchically related lineage-restricted fates of multipotent haematopoietic stem cells","volume":"554","author":"Carrelha","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2020.09.196_bib0069","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/nature25168","article-title":"Clonal analysis of lineage fate in native haematopoiesis","volume":"553","author":"Rodriguez-Fraticelli","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2020.09.196_bib0070","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.leukres.2013.08.015","article-title":"The clinical significance of cereblon expression in multiple myeloma","volume":"38","author":"Schuster","year":"2014","journal-title":"Leuk Res"},{"key":"10.1016\/j.exphem.2020.09.196_bib0071","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1182\/blood-2016-02-698092","article-title":"Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes","volume":"128","author":"Kort\u00fcm","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2020.09.196_bib0072","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1182\/blood-2014-02-557819","article-title":"Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma","volume":"124","author":"Zhu","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2020.09.196_bib0073","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1038\/leu.2016.384","article-title":"IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM)","volume":"31","author":"Kr\u00f6nke","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2020.09.196_bib0074","article-title":"Multiple Cereblon genetic changes associate with acquired resistance to lenalidomide or pomalidomide in multiple myeloma","author":"Gooding","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2020.09.196_bib0075","doi-asserted-by":"crossref","first-page":"11009","DOI":"10.1074\/jbc.M110.180208","article-title":"Evidence of a role for activation of Wnt\/beta-catenin signaling in the resistance of plasma cells to lenalidomide","volume":"286","author":"Bjorklund","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.exphem.2020.09.196_bib0076","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/leu.2013.174","article-title":"Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications","volume":"28","author":"Bjorklund","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2020.09.196_bib0077","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/leu.2014.238","article-title":"In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone","volume":"29","author":"Ocio","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2020.09.196_bib0078","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/s41375-019-0620-8","article-title":"Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN","volume":"34","author":"Bjorklund","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2020.09.196_bib0079","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1056\/NEJMoa0912228","article-title":"Persistent malignant stem cells in del(5q) myelodysplasia in remission","volume":"363","author":"Tehranchi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2020.09.196_bib0080","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1038\/leu.2013.59","article-title":"A G polymorphism in the CRBN gene acts as a biomarker of response to treatment with lenalidomide in low\/int-1 risk MDS without del(5q)","volume":"27","author":"Sardnal","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2020.09.196_bib0081","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1200\/JCO.2010.31.8576","article-title":"TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression","volume":"29","author":"J\u00e4dersten","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2020.09.196_bib0082","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1038\/onc.2012.139","article-title":"Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion","volume":"32","author":"Wei","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.exphem.2020.09.196_bib0083","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3324\/haematol.2016.152025","article-title":"Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations","volume":"102","author":"Scharenberg","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2020.09.196_bib0084","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1158\/1078-0432.CCR-15-1076","article-title":"A phase 2 trial of AZD6244 (Selumetinib, ARRY-142886), an oral MEK1\/2 inhibitor, in relapsed\/refractory multiple myeloma","volume":"22","author":"Holkova","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2020.09.196_bib0085","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1038\/s41375-019-0403-2","article-title":"RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradation","volume":"33","author":"Zhou","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2020.09.196_bib0086","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1182\/blood-2018-01-821769","article-title":"Genome-wide screen identifies cullin-RING ligase machinery required for lenalidomide-dependent CRL4CRBN activity","volume":"132","author":"Sievers","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2020.09.196_bib0087","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/s41375-018-0205-y","article-title":"A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity","volume":"33","author":"Liu","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2020.09.196_bib0088","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/j.1365-2141.2007.06833.x","article-title":"Gene expression profiling of CD34+ cells in patients with the 5q\u2013 syndrome","volume":"139","author":"Boultwood","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2020.09.196_bib0089","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/ncb1741","article-title":"A three-step pathway comprising PLZF\/miR-146a\/CXCR4 controls megakaryopoiesis","volume":"10","author":"Labbaye","year":"2008","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.exphem.2020.09.196_bib0090","doi-asserted-by":"crossref","first-page":"4666","DOI":"10.1182\/blood-2010-12-324715","article-title":"Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5q\u2013 syndrome","volume":"118","author":"Kumar","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2020.09.196_bib0091","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3324\/haematol.2012.066068","article-title":"Correlation of clinical response and response duration with miR-145 induction by lenalidomide in CD34(+) cells from patients with del(5q) myelodysplastic syndrome","volume":"98","author":"Venner","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2020.09.196_bib0092","doi-asserted-by":"crossref","first-page":"15589","DOI":"10.1074\/jbc.M801923200","article-title":"Tumor suppressor protein p53 regulates megakaryocytic polyploidization and apoptosis","volume":"283","author":"Fuhrken","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.exphem.2020.09.196_bib0093","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.exphem.2020.05.001","article-title":"Cyclosporine enhances the sensitivity to lenalidomide in MDS\/AML in vitro","volume":"86","author":"He","year":"2020","journal-title":"Exp Hematol"},{"key":"10.1016\/j.exphem.2020.09.196_bib0094","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1182\/blood-2012-04-421172","article-title":"The calcineurin\u2013NFAT pathway negatively regulates megakaryopoiesis","volume":"121","author":"Zaslavsky","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2020.09.196_bib0095","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.cell.2018.07.045","article-title":"Small molecules co-targeting CKI\u03b1 and the transcriptional kinases CDK7\/9 control AML in preclinical models","volume":"175","author":"Minzel","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.exphem.2020.09.196_bib0096","doi-asserted-by":"crossref","first-page":"6648","DOI":"10.1021\/acs.jmedchem.9b01928","article-title":"Discovery of CRBN E3 ligase modulator CC-92480 for the treatment of relapsed and refractory multiple myeloma","volume":"63","author":"Hansen","year":"2020","journal-title":"J Med Chem"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X20305610?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X20305610?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:35:07Z","timestamp":1759566907000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X20305610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":96,"alternative-id":["S0301472X20305610"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2020.09.196","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanisms of lenalidomide sensitivity and resistance","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2020.09.196","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 ISEH -- Society for Hematology and Stem Cells. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}